Ποια είναι η τιμή για Nabriva Therapeutics plc (NBRV)

Η τιμή για Nabriva Therapeutics plc (NBRV) είναι $0.63

Ποια είναι η κεφαλαιοποίηση αγοράς για Nabriva Therapeutics plc (NBRV)

Η κεφαλαιοποίηση αγοράς για Nabriva Therapeutics plc (NBRV) είναι $284.20K

Nabriva Therapeutics plc (NBRV) Τιμή και Κεφαλαιοποίηση Αγοράς

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

Η τιμή για NBRV	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$12,124,540 $284.20K	NVDA	$5.470T	+1,924,530,116.78%
$9,902,333 $284.20K	AAPL	$4.467T	+1,571,798,808.82%
$9,253,527 $284.20K	GOOG	$4.174T	+1,468,813,723.90%
$8,202,107 $284.20K	MSFT	$3.700T	+1,301,921,721.47%
$6,327,334 $284.20K	AMZN	$2.854T	+1,004,338,657.17%

Η τιμή για NBRV

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$12,124,540 $284.20K